Researchers at Vanderbilt University Medical Center and their colleagues are a step closer to developing a broadly effective antibody treatment against the three major Ebola viruses that cause lethal disease in humans.

A drug used to treat diabetes may point to new therapies for respiratory syncytial virus (RSV) bronchiolitis — inflammation and obstruction of the lungs’ small airways. A multi-disciplinary team of Vanderbilt investigators has demonstrated that liraglutide reduces the inflammatory response to RSV infection in a mouse model of the disease.

Jun. 28, 2018—The new factor, an enzyme involved in host-pathogen interactions, may be a viable target for treating staph infections.

Vanderbilt researchers describe how certain tuberculosis treatments work and suggest these medications may overcome the threat of drug-resistant tuberculosis.

A new integrated imaging approach makes it possible to probe the molecules involved in invasive infections and can be broadly applied to any health or disease state.

Newly discovered features in an RSV protein may be useful for rational structure-based vaccine design.

Opioid users have a significantly increased risk of infections severe enough to require treatment at the hospital, such as pneumonia and meningitis, as compared to people who don’t use opioids.